Cover Image
市場調查報告書

日光角化症:開發中產品分析

Actinic (Solar) Keratosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192432
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
日光角化症:開發中產品分析 Actinic (Solar) Keratosis - Pipeline Review, H1 2017
出版日期: 2017年04月11日 內容資訊: 英文 64 Pages
簡介

光線角化症,也稱為日光角化症,是鱗狀或硬皮的皮膚病變。最常見於沒頭髮的頭皮、臉、耳朵、嘴唇、手背、前臂後部、肩膀、頭等,頻繁曝曬日光的身體其他部位。徵兆與症狀是硬、疣狀表面,斑點,皮膚最上層的瘤,患部癢和刺痛的感覺,顏色是粉色、紅、茶色、膚色等。原因為年齡,陽光充足的氣候,非常強的日光曝曬和曬黑的頻率,蒼白的皮膚,紅、金髮,青、淡色的眼睛,化療造成免疫系統衰弱,慢性白血病,愛滋病,器官移植的投藥等。

本報告提供日光角化症的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

日光角化症概要

治療藥的開發

  • 開發中產品的概要
  • 企業開發中的治療藥
  • 大學/機關研究中的治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

日光角化症:治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發日光角化症的治療藥的企業

  • 3M Drug Delivery Systems
  • Athenex Inc
  • CritiTech Inc
  • Foamix Pharmaceuticals Ltd
  • G&E Herbal Biotechnology Co Ltd
  • Galderma SA
  • Laboratories Ojer Pharma SL
  • LEO Pharma A/S
  • Novartis AG
  • Oncology Research International Ltd
  • Promius Pharma LLC
  • Valeant Pharmaceuticals International Inc
  • Vectura Group Plc

藥物簡介

  • 854-A
  • ACT-01
  • AD-17137
  • celecoxib
  • DFD-08
  • GDC-695
  • hydrogen peroxide + sulindac
  • IDP-125
  • IDP-128
  • imiquimod
  • imiquimod SR
  • ingenol disoxate
  • KX-01
  • LFX-453
  • ORIL-007
  • paclitaxel
  • resiquimod
  • SKP-024
  • 光線角化症及非黑色素瘤皮膚癌症用活化蛋白激酶C的小分子
  • SRT-100
  • VDA-1102

日光角化症:暫停中的計劃

日光角化症:中止開發的產品

日光角化症:產品開發里程碑

  • 主要消息和新聞稿

附錄

免責聲明

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9172IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2017, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.

An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 1, 6, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Actinic (Solar) Keratosis - Overview
    • Actinic (Solar) Keratosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Actinic (Solar) Keratosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Athenex Inc
    • CritiTech Inc
    • Foamix Pharmaceuticals Ltd
    • G&E Herbal Biotechnology Co Ltd
    • Galderma SA
    • Laboratories Ojer Pharma SL
    • LEO Pharma A/S
    • Novartis AG
    • Oncology Research International Ltd
    • Promius Pharma LLC
    • Valeant Pharmaceuticals International Inc
    • Vectura Group Plc
  • Actinic (Solar) Keratosis - Drug Profiles
    • 854-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AD-17137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • celecoxib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DFD-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GDC-695 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydrogen peroxide + sulindac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IDP-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IDP-128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ingenol disoxate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KX-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LFX-453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORIL-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paclitaxel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • resiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKP-024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VDA-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Actinic (Solar) Keratosis - Dormant Projects
  • Actinic (Solar) Keratosis - Discontinued Products
  • Actinic (Solar) Keratosis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 12, 2016: Vidac Pharma Phase 2 Study Of VDA-1102 In Actinic Keratosis Meets Interim Analysis Criterion
      • Jul 29, 2016: Vidac Pharma Announces The Innitiation Of A Phase 2 Study Of VDA-1102 Ointment In Patients With Actinic Keratosis
      • Jun 30, 2016: Vidac Pharma Completes Phase 1A Trial Of VDA-1102 Ointment
      • Feb 25, 2016: Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator
      • Dec 30, 2015: Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis
      • Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Actinic (Solar) Keratosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Athenex Inc, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by CritiTech Inc, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Galderma SA, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Novartis AG, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Promius Pharma LLC, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
  • Actinic (Solar) Keratosis - Pipeline by Vectura Group Plc, H1 2017
  • Actinic (Solar) Keratosis - Dormant Projects, H1 2017
  • Actinic (Solar) Keratosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Actinic (Solar) Keratosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Actinic (Solar) Keratosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top